<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227015</url>
  </required_header>
  <id_info>
    <org_study_id>BHCT-CTA101-08</org_study_id>
    <nct_id>NCT04227015</nct_id>
  </id_info>
  <brief_title>A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy</brief_title>
  <official_title>A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>He Huang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing Bioheng Biotech Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line&#xD;
      hematological malignancy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, open-label, single-center study. This study is indicated for relapsed&#xD;
      or refractory CD19+ B-line hematological malignancy: B-ALL and B-NHL. the selection of dose&#xD;
      levels and the number of subjects are based on clinical tiral of similar foreign products. 2&#xD;
      groups of patients will be enrolled, 36 in each group. Primary objective is to explore the&#xD;
      safety, main consideration is dose-related safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 8, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>Baseline up to 28 days after CTA101 infusion</time_frame>
    <description>Adverse events assessed according to NCI-CTCAE v5.0 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 2 years after CTA101 infusion</time_frame>
    <description>Incidence of treatment-emergent adverse events [Safety and Tolerability]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>B-cell acute lymphocytic leukemia (B-ALL), MRD negative overall response rate (MRD- ORR)</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of MRD negative overall response rate (MRD- ORR) at 3 months after CTA101 infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-ALL, Event-free survival (EFS)</measure>
    <time_frame>Month 6, 12, 18 and 24</time_frame>
    <description>From the first infusion of CTA101 to the occurrence of any event, including death, relapse or gene relapse, disease progression (any one occurs first), and the last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-ALL, Overall response rate (ORR)</measure>
    <time_frame>Month 6, 12, 18 and 24</time_frame>
    <description>Assessment of ORR (ORR = CR + CRi ) at Month 6, 12, 18 and 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-ALL, Overall survival (OS)</measure>
    <time_frame>Month 6, 12, 18 and 24</time_frame>
    <description>From the first infusion of CTA101 to death or the last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B cell non-hodgkin's lymphoma (B-NHL), Overall response rate (ORR)</measure>
    <time_frame>weeks 4, 12, months 6, 12, 18 and 24</time_frame>
    <description>Assessment of ORR (ORR = CR + PR ) per Lugano 2014 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-NHL,disease control rate (DCR)</measure>
    <time_frame>weeks 12, months 6, 12, 18 and 24</time_frame>
    <description>Assessment of DCR (DCR=CR+PR+SD) per Lugano 2014 criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Non-hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Administration of CTA101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation follows the standard 3+3 dose escalation design. A total of 2 dose levels are set for subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTA101</intervention_name>
    <description>CTA101 UCAR-T cell injection by intravenous infusion</description>
    <arm_group_label>Administration of CTA101</arm_group_label>
    <other_name>CTA101 UCAR-T cell injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria applicable to ALL only:&#xD;
&#xD;
          1. Male or female aged ≥ 3 and &lt;70 years old;&#xD;
&#xD;
          2. Histologically confirmed diagnosis of CD19+ B-ALL per the US National Comprehensive&#xD;
             Cancer Network (NCCN) Clinical Practice Guidelines for Acute Lymphoblastic Leukemia&#xD;
             (2016.v1);&#xD;
&#xD;
          3. Relapsed or refractory CD19+ B-ALL (meeting one of the following conditions):&#xD;
&#xD;
               1. CR not achieved after standardized chemotherapy;&#xD;
&#xD;
               2. CR achieved following the first induction, but CR duration is ≤ 12 months;&#xD;
&#xD;
               3. Ineffective after first or multiple remedial treatments;&#xD;
&#xD;
               4. 2 or more recurrences;&#xD;
&#xD;
          4. The number of primordial cells (lymphoblast and prolymphocyte) in bone marrow is &gt;5%&#xD;
             (morphology) and/or &gt;1% (Flow cytometry);&#xD;
&#xD;
          5. Philadelphia-chromosome-negative (Ph-) patients; or Philadelphia-chromosome-positive&#xD;
             (Ph+) patients who cannot tolerate TKI treatments or do not respond to 2 TKI&#xD;
             treatments;&#xD;
&#xD;
        Inclusion criteria applicable to NHL only:&#xD;
&#xD;
          1. Male or female aged ≥ 18 and &lt;70 years old;&#xD;
&#xD;
          2. Histologically confirmed diagnosis per WHO Classification Criteria for Lymphocytic&#xD;
             Tumors 2016, including DLBCL(NOS), follicular lymphoma, Chronic lymphoblastic&#xD;
             leukemia/small lymphoblastic lymphoma transforms DLBCL, PMBCL and high grade B cell&#xD;
             lymphoma;&#xD;
&#xD;
          3. Relapsed or refractory DLBCL (meeting one of the following conditions):&#xD;
&#xD;
               1. No remission or recurrence after receiving second-line or above second-line&#xD;
                  chemotherapy;&#xD;
&#xD;
               2. Primary drug resistance;&#xD;
&#xD;
               3. Recurrence after autologous hematopoietic stem cell transplantation&#xD;
&#xD;
          4. According to Lugano 2014, there should be at least one evaluable tumor lesion.&#xD;
&#xD;
        Applicable standards for ALL and NHL:&#xD;
&#xD;
          1. HLA antibody(-) or HLA antibody(+) and HLA donor specific antibody(DSA)(-);&#xD;
&#xD;
          2. total bilirubin ≤ 51umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine&#xD;
             ≤ 176.8umol/L;&#xD;
&#xD;
          3. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%;&#xD;
&#xD;
          4. No active infection in the lungs, blood oxygen saturation by sucking air is ≥ 92%;&#xD;
&#xD;
          5. Estimated survival time ≥ 3 months;&#xD;
&#xD;
          6. ECOG performance status 0 to 2;&#xD;
&#xD;
          7. Patients or their legal guardians volunteer to participate in the study and sign the&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients with extramedullary lesions, except those with CNSL (CNS-1) under effective&#xD;
             control (for ALL patients only);&#xD;
&#xD;
          2. Confirmed diagnosis of lymphoblastic crisis of chronic myeloid leukemia, Burkitt's&#xD;
             leukemia/lymphoma per WHO Classification Criteria (for ALL patients only);&#xD;
&#xD;
          3. Patients with hereditary syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman&#xD;
             syndrome or any other known bone marrow failure syndrome (for ALL patients only);&#xD;
&#xD;
          4. patients with intracranial extralateral lesions (cerebrospinal fluid tumor cells&#xD;
             and/or intracranial lymphoma invasion shown by MRI) (for NHL patients only) ;&#xD;
&#xD;
          5. extensive involvement of gastrointestinal lymphoma (for NHL patients only);&#xD;
&#xD;
          6. radiotherapy, chemotherapy and monoclonal antibody within 1 week before screening;&#xD;
&#xD;
          7. Have a history of allergy to any of the components in the cell products;&#xD;
&#xD;
          8. Prior treatment with any CAR T cell product or other genetically-modified T cell&#xD;
             therapies;&#xD;
&#xD;
          9. According to the New York heart association (NYHA) cardiac function classification&#xD;
             criteria, Subjects with grade III or IV cardiac insufficiency;&#xD;
&#xD;
         10. Myocardial infarction, cardioangioplasty or stenting, unstable angina pectoris, or&#xD;
             other severe cardiac diseases within 12 months of enrollment;&#xD;
&#xD;
         11. Severe primary or secondary hypertension of grade 3 or above (WHO Hypertension&#xD;
             Guidelines, 1999);&#xD;
&#xD;
         12. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe&#xD;
             arrhythmia in the past;&#xD;
&#xD;
         13. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular&#xD;
             ischemia, and cerebrovascular hemorrhagic diseases;&#xD;
&#xD;
         14. Patients with severe active infections (excluding simple urinary tract infection and&#xD;
             bacterial pharyngitis).&#xD;
&#xD;
         15. Indwelling catheters in vivo (e.g. percutaneous nephrostomy, Foley catheter, bile duct&#xD;
             catheter, or pleural/peritoneal/pericardial catheter). Ommaya storage, dedicated&#xD;
             central venous access catheters such as Port-a-Cath or Hickman catheters are allowed;&#xD;
&#xD;
         16. History of other primary cancer, except for the following conditions:&#xD;
&#xD;
               1. Cured non-melanoma after resection, such as basal cell carcinoma of the skin;&#xD;
&#xD;
               2. Cervical cancer in situ, localized prostate cancer, ductal cancer in situ with&#xD;
                  disease-free survival ≥ 2 years after adequate treatment;&#xD;
&#xD;
         17. Patients with autoimmune diseases requiring treatment, patients with immunodeficiency&#xD;
             or requiring immunosuppressive therapy;&#xD;
&#xD;
         18. Patients with graft-versus-host disease (GVHD);&#xD;
&#xD;
         19. Prior immunizations with live vaccine 4 weeks prior to screening;&#xD;
&#xD;
         20. History of alcoholism, drug abuse or mental illness;&#xD;
&#xD;
         21. If HBsAg positive at screening, HBV DNA copy number detected by PCR in patients with&#xD;
             active hepatitis B &gt; 1000 (if HBV DNA copy number≤1000, routine antiviral therapy is&#xD;
             required after enrollment), as well as CMV, hepatitis C, syphilis infection;&#xD;
&#xD;
         22. Concurrent therapy with systemic steroids within 1 week prior to screening, except for&#xD;
             the patients recently or currently receiving inhaled steroids;&#xD;
&#xD;
         23. Patients who have participated in any other clinical studies within 2 weeks prior to&#xD;
             screening;&#xD;
&#xD;
         24. pregnant and breast-feeding women and the subjects who are fertile and unable to take&#xD;
             effective contraceptive measures (regardless of the gender);&#xD;
&#xD;
         25. Any situations that the investigator believes may increase the risk of patients or&#xD;
             interfere with the results of study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Hospital of Zhejiang Medical Colleage Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>He Huang, MD</last_name>
      <phone>86-13605714822</phone>
      <email>hehuangyuzj@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jimin Shi, MD</last_name>
      <phone>86-13857119907</phone>
      <email>jiminshi@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>He Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>December 24, 2020</last_update_submitted>
  <last_update_submitted_qc>December 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>He Huang</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

